Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Philippe Bouvet has worked on the following 10 EPO patent applications which have been published in the last five years:

EP11290232

Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms

IPC classification:
A61K 47/48, C07K 16/28
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Agent:
Philippe Bouvet, Sanofi-Aventis
Status:
APPLICATION REFUSED
EP12704842

SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS

IPC classification:
C12Q 1/68
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
GRANT OF PATENT INTENDED
EP12706541

METHOD OF PRODUCTION OF SIALYLATED ANTIBODIES

IPC classification:
C07K 16/18
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
GRANT OF PATENT INTENDED
EP11305999

Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab

IPC classification:
A61K 39/395, A61K 47/48, A61P 35/00, C07K 16/28
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12717129

COMPOSITION COMPRISING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACIL (5-FU) AND IRINOCETAN (FOLFIRI)

IPC classification:
A61K 31/4745, A61K 31/505, A61K 31/519, A61K 38/17, A61P 35/00
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
PATENT GRANTED
EP12769684

COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME

IPC classification:
A61K 31/42, A61K 31/519, A61K 31/655, A61K 39/395, A61K 45/06, C07K 16/28
Applicant:
Sanofi, S.A.
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
BĂ©atrice Holtz, Cabinet Lavoix
Agent:
Philippe Bouvet, Sanofi
Status:
GRANT OF PATENT INTENDED
EP13745404

ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT

IPC classification:
A61K 9/00, A61K 31/4745, A61K 31/513, A61K 31/519, A61K 38/18, A61P 35/00
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
EXAMINATION IN PROGRESS
EP13794894

ANTI-CEACAM5 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/30
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
PATENT GRANTED
EP15738625

METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER

IPC classification:
G01N 33/574
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
EXAMINATION REQUESTED
EP17157890

ANTI-CEACAM5 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/30
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
The application has been published

Please Sign in to use this feature